Israeli drug development company BioLineRX has announced that it will receive an $8 million investment from OrbiMed Israel Partners LP. BioLineRX says that it will use the funds to continue the development of its clinical and pre-clinical state therapeutic assets.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments